Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL468815 | 1.00 | KDM4E (0.45) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL1576871 | 1.00 | KDM4E (0.45) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL15826905 | 0.85 | MAPT (0.48) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL1909473 | 0.85 | MAPT (0.48) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL16494295 | 0.84 | GNPAT (0.56) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL13930086 | 0.84 | ECE1 (0.44) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL27857327 | 0.84 | GNPAT (0.56) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL8134268 | 0.81 | KDM4E (0.45) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL13953561 | 0.81 | KDM4E (0.45) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL27410307 | 0.81 | KDM4E (0.45) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2311452-B2 | Topical composition comprising n-acetyl glucosamine | YU RUEY J (US) | 2020-12-30 | — | — | EP | disclosed |
| US-10869846-B2 | N-acetylcysteine amide (NAC amide) in the treatment of diseases and conditions associated with oxidative stress | SENTIENT LIFESCIENCES, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190111009-A1 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) IN THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS | SENTIENT LIFESCIENCES, INC. | 2019-04-18 | — | — | US | disclosed |
| US-20160206576-A1 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) IN THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS | GOLDSTEIN GLENN A (US) | 2016-07-21 | — | — | US | disclosed |
| US-20160206576-A1 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) IN THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS | GOLDSTEIN GLENN A (US) | 2016-07-21 | — | — | US | disclosed |
| US-9216162-B2 | N-acetylcysteine amide (NAC amide) in the treatment of diseases and conditions associated with oxidative stress | GOLDSTEIN GLENN A (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216162-B2 | N-acetylcysteine amide (NAC amide) in the treatment of diseases and conditions associated with oxidative stress | GOLDSTEIN GLENN A (US) | 2015-12-22 | — | — | US | disclosed |
| US-8993627-B2 | N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress | SENTIENT LIFESCIENCES, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993627-B2 | N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress | SENTIENT LIFESCIENCES, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8937099-B2 | N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress | SENTIENT LIFESCIENCES, INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-20090234011-A1 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS | DAVID PHARMACEUTICALS | 2009-09-17 | — | — | US | disclosed |
| US-20090234011-A1 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS | DAVID PHARMACEUTICALS | 2009-09-17 | — | — | US | disclosed |
| EP-2080504-A2 | Topical composition comprising n-acetylaldosamines or n-acetylamino acids | Yu, Ruey J. (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080051401-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | PASS MARTIN | 2008-02-28 | — | — | US | disclosed |
| EP-1639994-A2 | Topical composition comprising N-acetylaldosamines or N-acetylamino acids | Yu, Ruey J., Dr. (US) | 2006-03-29 | — | — | EP | disclosed |
| EP-1570840-A2 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | Yu, Ruey J., Dr. (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6524593-B1 | Alleviate or improve various cosmetic conditions and dermatological disorders, skin, hair, nails | TRISTRATA, INC. | 2003-02-25 | — | — | US | disclosed |
| EP-1143925-A1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | Yu, Ruey J., Dr. (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6159485-A | COSMETICS; SKIN DISORDERS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-12-12 | — | — | US | disclosed |
| WO-2000040217-A1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160206576-A1 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) IN THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS | GCLC, NAT1, HHAT | KDM4E 4864/4885MAPT 1059/4885THRB 1957/4885 |
| US-10869846-B2 | N-acetylcysteine amide (NAC amide) in the treatment of diseases and conditions associated with oxidative stress | GCLC, NAT1, HHAT | KDM4E 4864/4885MAPT 1059/4885THRB 1957/4885 |
| US-20080051401-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | PIK3CA, TYMP, PIK3CB | KDM4E 1370/4885MAPT 3363/4885THRB 2731/4885 |
| US-20190111009-A1 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) IN THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS | GCLC, NAT1, HHAT | KDM4E 4864/4885MAPT 1059/4885THRB 1957/4885 |
| US-20090234011-A1 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS | GCLC, NAT1, HHAT | KDM4E 4862/4885MAPT 1119/4885THRB 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.